Q3 2023 · 13F-HR
MPM BioImpact LLCholdings as filed
Filed 2023-11-14 · accession 0000950123-23-010967
$374.6M
Reported value
32
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 230031106 | CGEM | Cullinan Oncology, Inc. | $69.2M | 18.5% | 7,648,268 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals, Inc. | $22.9M | 6.12% | 1,857,681 | Common | SOLE |
| 374163103 | GERN | Geron Corporation | $22.7M | 6.06% | 10,712,481 | Common | SOLE |
| 760273102 | RPTX | Repare Therapeutics, Inc. | $19.8M | 5.29% | 1,639,849 | Common | SOLE |
| 46565G104 | 5E7 | iTeos Therapeutics, Inc. | $19.1M | 5.10% | 1,745,943 | Common | SOLE |
| 45826J105 | NTLA | Intellia Therapeutics, Inc. | $17.2M | 4.60% | 544,639 | Common | SOLE |
| 61559X104 | MLTX | Moonlake Immunotherapeutics | $16.8M | 4.48% | 294,190 | Common | SOLE |
| 462260100 | IOVA | Iovance Biotherapeutics Inc | $15.0M | 3.99% | 3,287,397 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals Inc. | $14.2M | 3.80% | 479,053 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $13.3M | 3.56% | 527,458 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $11.6M | 3.11% | 230,761 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics, Inc | $11.4M | 3.04% | 857,940 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc. | $11.4M | 3.04% | 1,352,133 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO Inc. | $10.8M | 2.89% | 656,718 | Common | SOLE |
| 23257D103 | CBAYUSD | CYMABAY THERAPEUTICS INC | $9.1M | 2.43% | 610,770 | Common | SOLE |
| 48576A100 | — | Karuna Therapeutics Inc | $9.0M | 2.40% | 53,210 | Common | SOLE |
| 03152W109 | AM6 | Amicus Therapeutics Inc. | $8.7M | 2.32% | 716,139 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $7.6M | 2.02% | 273,408 | Common | SOLE |
| 98422E103 | XERS | Xeris Biopharma Holdings Inc | $7.4M | 1.98% | 3,987,967 | Common | SOLE |
| 05337M104 | — | Avadel Pharmaceuticals PLC | $6.8M | 1.83% | 664,224 | Common | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics, Inc. | $6.5M | 1.75% | 93,586 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals inc | $6.0M | 1.59% | 40,859 | Common | SOLE |
| 483497103 | KALV | Kalvista Pharmaceuticals Inc | $5.6M | 1.49% | 577,958 | Common | SOLE |
| 95075A107 | HOWL | Werewolf Therapeutics, Inc. | $5.1M | 1.36% | 2,388,011 | Common | SOLE |
| 89422G107 | TVTX | Travere Therapeutics Inc. | $4.9M | 1.32% | 552,846 | Common | SOLE |
| 61775R105 | MORFUSD | MORPHIC HOLDING INC | $4.6M | 1.22% | 200,000 | Common | SOLE |
| 00653A107 | ADAPY | Adaptimmune Therapeutics plc | $4.0M | 1.06% | 5,095,912 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics Inc | $3.9M | 1.05% | 255,323 | Common | SOLE |
| 71722W107 | PHAT | Phathom Pharmaceuticals inc | $3.6M | 0.96% | 347,332 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $3.6M | 0.96% | 325,000 | Common | SOLE |
| 45790W108 | — | Inozyme Pharma Inc. | $1.4M | 0.37% | 326,921 | Common | SOLE |
| 41358P205 | HARPUSD | Harpoon Therapeutics, Inc. | $1.3M | 0.34% | 319,670 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.